Tumor-derived Matrix Metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Zhang, Bin ^a   Cao, Xuchen ^a   Liu, Yanxue ^a   Cao, Wenfeng ^a   Zhang, Fei ^a   Zhang, Shiwu ^a   Li, Hongtao ^a   Ning, Liansheng ^a   Fu, Li ^a   Niu, Yun ^a   Niu, Ruifang ^a   Sun, Baocun ^a   Hao, Xishan ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GELATINASE A; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR ANTIGEN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER INFILTRATION; CANCER INVASION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; FEMALE; FIBROBLAST; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL; TISSUE DISTRIBUTION; TISSUE MICROARRAY; TUMOR VOLUME; BREAST TUMOR; DISEASE COURSE; ENZYMOLOGY; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL RATE;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYTOPLASM; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2; STROMAL CELLS; SURVIVAL RATE; TISSUE DISTRIBUTION; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 43049132504     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-83     Document Type: Article

References (42)

1. Yu KD Di GH Wu J Lu JS Shen KW Shen ZZ Shao ZM Development and Trends of Surgical Modalities for Breast Cancer in China: A Review of 16-Year Data Ann Surg Oncol 2007, 14:2502-2509. 10.1245/s10434-007-9436-2 17564750
2. Tavassoéli FA Devilee P Pathology and Genetics: Tumors of the Breast and Female Genital Organs Lyon: WHO Press;. IARC WHO Classification of Tumours, No. 4 2003
3. Choi DH Shin DB Lee MH Lee DW Dhandapani D Carter D King BL Haffty BG A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma Cancer 2003, 98:1587-1595. 10.1002/cncr.11703 14534873
4. Freije JM Díez-Itza I Balbín M Sánchez LM Blasco R Tolivia J López-Otín C Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas J Biol Chem 1996, 49:20-37.
5. Crawford HC Matrisian LM Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells Enzyme Protein 1996, 49:20-37. 8796995
6. Knäuper V López-Otin C Smith B Knight G Murphy G Biochemical characterization of human collagenase-3 J Biol Chem 1996, 271:1544-1550. 10.1074/jbc.271.3.1544 8576151
7. Ala-aho R Kähäri VM Collagenases in cancer Biochimie 2005, 87:273-86. 10.1016/j.biochi.2004.12.009 15781314
8. Leeman MF Curran S Murray GI The structure, regulation, and function of human matrix metalloproteinase-13 Crit Rev Biochem Mol Biol 2002, 37:149-166. 10.1080/10409230290771483 12139441
9. Pendas AM Uria JA Jimenez MG Balbin M Freije JP Lopez-Otin C An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies Clin Chim Acta 2000, 291:137-155. 10.1016/S0009-8981(99)00225-9 10675720
10. Balbin M Pendas AM Uria JA Jimenez MG Freije JP Lopez-Otin C Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors APMIS 1999, 107:45-53. 10190279
11. Corte MD Gonzalez LO Corte MG Quintela I Pidal I Bongera M Vizoso F Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma Int J Biol Markers 2005, 20:242-248. 16398406
12. Luukkaa M Vihinen P Kronqvist P Vahlberg T Pyrhönen S Kähäri VM Grénman R Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer Head Neck 2006, 28:225-234. 10.1002/hed.20322 16302191
13. Curran S Dundas SR Buxton J Leeman MF Ramsay R Murray GI Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers Clin Cancer Res 2004, 10:8229-8234. 10.1158/1078-0432.CCR-04-0424 15623598
14. Dünne AA Sesterhenn A Gerisch A Teymoortash A Kuropkat C Werner JA Expression of MMP-2, -9 and -13 in cell lines and fresh biopsies of squamous cell carcinomas of the upper aerodigestive tract Anticancer Res 2003, 23:2233-2239. 12894497
15. Bartsch JE Staren ED Appert HE Matrix metalloproteinase expression in breast cancer J Surg Res 2003, 110:383-392. 10.1016/ S0022-4804(03)00007-6 12788669
16. Leeman MF McKay JA Murray GI Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer J Clin Pathol 2002, 55:758-762. 1769766 12354802 10.1136/jcp.55.10.758
17. Boström PJ Ravanti L Reunanen N Aaltonen V Söderström KO Kähäri VM Laato M Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder Int J Cancer 2000, 88:417-423. 10.1002/ 1097-0215(20001101)88:3<417::AID-IJC14>3.0.CO;2-G 11054671
18. Luukkaa M Vihinen P Kronqvist P Vahlberg T Pyrhönen S Kähäri VM Grénman R Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer Head Neck 2006, 28:225-234. 10.1002/hed.20322 16302191
19. Curran S Dundas SR Buxton J Leeman MF Ramsay R Murray GI Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers Clin Cancer Res 2004, 10:8229-8234. 10.1158/1078-0432.CCR-04-0424 15623598
20. Culhaci N Metin K Copcu E Dikicioglu E Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness BMC Cancer 2004, 4:42. 512290 15291964 10.1186/ 1471-2407-4-42
21. Balduyck M Zerimech F Gouyer V Lemaire R Hemon B Grard G Thiebaut C Lemaire V Dacquembronne E Duhem T Lebrun A Dejonghe MJ Huet G Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro Clin Exp Metastasis 2000, 18:171-178. 10.1023/A:1006762425323 11235993
22. Daja MM Niu X Zhao Z Brown JM Russell PJ Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines Prostate Cancer Prostatic Dis 2003, 6:15-26. 10.1038/sj.pcan.4500609 12664060
23. Airola K Karonen T Vaalamo M Lehti K Lohi J Kariniemi AL Keski-Oja J Saarialho-Kere UK Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas Br J Cancer 1999, 80:733-743. 10.1038/sj.bjc.6690417 10360651
24. Johansson N Vaalamo M Grénman S Hietanen S Klemi P Saarialho-Kere U Kähäri VM Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas Am J Pathol 1999, 154:469-480. 1849989 10027405
25. Nielsen BS Rank F Lopez JM Balbin M Vizoso F Lund LR Dano K Lopez-Otin C Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas Cancer Res 2001, 61:7091-7100. 11585740
26. Engelholm LH Nielsen BS Netzel-Arnett S Solberg H Chen XD Lopez Garcia JM Lopez-Otin C Young MF Birkedal-Hansen H Danà K Lund LR Behrendt N Bugge TH The urokinase plasminogen activator receptor-associated protein/endo180 is coexpressed with its interaction partners urokinase plasminogen activator receptor and matrix metalloprotease-13 during osteogenesis Lab Invest 2005, 81:1403-14.
27. Cao WF Zhang B Liu YX SLP-2 high expression associated with HER2/neu protein expression decreased breast cancer patient survival Am J Clin Pathol 2007, 128:430-436. 10.1309/C6X54HRB580EP2NQ 17709317
28. Riley SC Leask R Denison FC Wisely K Calder AA Howe DC Secretion of tissue inhibitors of matrix metalloproteinases by human fetal membranes, decidua and placenta at parturition J Endocrinol 1999, 162:351-359. 10.1677/joe.0.1620351 10467226
29. Demir-Weusten AY Seval Y Kaufmann P Demir R Yucel G Huppertz B Matrix metalloproteinases-2, -3 and -9 in human term placenta Acta Histochem 2007, 109:403-412. 10.1016/j.acthis.2007.04.001 17559909
30. Takai N Jain A Kawamata N Popoviciu LM Said JW Whittaker S Miyakawa I Agus DB Koeffler HP 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth Cancer 2005, 104:2701-2708. 10.1002/cncr.21533 16265675
31. Carlson RW Moench SJ Hammond EH Perez EA Burstein HJ Allred C Vogel CL Goldstein LJ Somio G Gradishar WJ HER2 testing in breast cancer:NCCN task force report and recommendations J Natl Compr Canc Netw 2006, 4(Suppl 3):S1-S22. quiz S23-S24 16813731
32. O-Charoenrat P Rhys-Evans PH Eccles SA Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck Arch Otolaryngol Head Neck Surg 2001, 127:813-820. 11448356
33. Charous SJ Stricklin GP Nanney LB Netterville JL Burkey BB Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma Ann Otol Rhinol Laryngol 1997, 106:271-278. 9109715
34. Vizoso FJ Gonzalez LO Corte MD Rodriguez JC Vazquez J Lamelas ML Junquera S Merino AM Garcia-Muniz JL Study of matrix metalloproteinase and their inhibitors in breast cancer Br J Cancer 2007, 96:903-11. 10.1038/sj.bjc.6603666 17342087
35. O-charoenrat P Rhys-Evans PH Archer DJ Eccles SA C-erbB receptors in squamous cell carcinomas of the head and neck: Clinical significance and correlation with matrix metalloproteinase and vascular endothelial growth factors Oral Oncol 2002, 38:73-80. 10.1016/S1368-8375(01)00029-X 11755824
36. Jinga DC Blidaru A Condrea I Ardeleanu C Dragomir C Szegli G Stefanescu M Matache C MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: Correlations with prognostic factors J Cell Mol Med 2006, 10:499-510. 10.1111/j.1582-4934.2006.tb00415.x 16796815
37. Kuvaja P Talvensaari-Mattila A Paakko P Turpeenniemi-Hujanen T The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma Oncology 2005, 68:196-203. 10.1159/000086774 16006757
38. Li HC Cao DC Liu Y Hou YF Wu J Lu JS Di GH Liu G Li FM Ou ZL Jie C Shen ZZ Shao ZM Prognostic value of matrix metalloproteinase (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma Breast Cancer Res Treat 2004, 88:75-85. 10.1007/s10549-004-1200-8 15538048
39. Tetu B Brisson J Wang CS Lapointe H Beaudry G Blanchette C Trudel D The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis Breast Cancer Res 2006, 8:R28. 1557730 16776850 10.1186/bcr1503
40. Hornebeck W Lambert E Petitfrere E Bernard P Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression Biochimie 2005, 87:377-83. 10.1016/j.biochi.2004.09.022 15781325
41. Liu SC Yang SF Yeh KT Yeh CM Chiou HL Lee CY Chou MC Hsieh YS Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer Clin Chim Acta 2006, 371:92-96. 10.1016/ j.cca.2006.02.026 16581051
42. Wurtz SO Schrohl AS Sorensen NM Lademann U Christensen IJ Mouridsen H Brunner N Tissue inhibitor of metalloproteinases-1 in breast cancer Endocr Relat Cancer 2005, 12:215-27. 10.1677/erc.1.00719 15947098